BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22993325)

  • 1. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer.
    Song M; Cheong JH; Kim H; Noh SH; Kim H
    Anticancer Res; 2012 Sep; 32(9):3827-34. PubMed ID: 22993325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis.
    Salcedo Allende MT; Zeron-Medina J; Hernandez J; Macarulla T; Balsells J; Merino X; Allende H; Tabernero J; Ramon Y Cajal S
    Pancreas; 2017 Aug; 46(7):913-920. PubMed ID: 28697132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.
    Kang W; Tong JH; Chan AW; Lee TL; Lung RW; Leung PP; So KK; Wu K; Fan D; Yu J; Sung JJ; To KF
    Clin Cancer Res; 2011 Apr; 17(8):2130-9. PubMed ID: 21346147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Yes-associated protein 1 with concomitant negative LATS1/2 expression is associated with poor prognosis of advanced gastric cancer.
    Kim E; Ahn B; Oh H; Lee YJ; Lee JH; Lee Y; Kim CH; Chae YS; Kim JY
    Pathology; 2019 Apr; 51(3):261-267. PubMed ID: 30819540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic characteristics of YES-associated protein 1 overexpression and its relationship to tumor biomarkers in gastric cancer.
    Zhang J; Yang YC; Zhu JS; Zhou Z; Chen WX
    Int J Immunopathol Pharmacol; 2012; 25(4):977-87. PubMed ID: 23298488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low angiomotin-p130 with concomitant high Yes-associated protein 1 expression is associated with adverse prognosis of advanced gastric cancer.
    Hong SA; Son MW; Cho J; Jang SH; Lee HJ; Lee JH; Cho HD; Oh MH; Lee MS
    APMIS; 2017 Nov; 125(11):996-1006. PubMed ID: 28885730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct prognostic values of YAP1 in gastric cancer.
    Yu L; Gao C; Feng B; Wang L; Tian X; Wang H; Ma D
    Tumour Biol; 2017 Apr; 39(4):1010428317695926. PubMed ID: 28381174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells.
    Diep CH; Zucker KM; Hostetter G; Watanabe A; Hu C; Munoz RM; Von Hoff DD; Han H
    PLoS One; 2012; 7(3):e32783. PubMed ID: 22396793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients.
    Cha YJ; Kim D; Bae SJ; Ahn SG; Jeong J; Cho MK; Paik PS; Yoo TK; Park WC; Yoon CI
    PLoS One; 2021; 16(5):e0250986. PubMed ID: 33970925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
    Sun D; Li X; He Y; Li W; Wang Y; Wang H; Jiang S; Xin Y
    Oncotarget; 2016 Dec; 7(49):81062-81076. PubMed ID: 27835600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1.
    Deng J; Lei W; Xiang X; Zhang L; Yu F; Chen J; Feng M; Xiong J
    Tumour Biol; 2015 Sep; 36(9):6823-31. PubMed ID: 25846731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of Nodal and YAP1 is associated with poor prognosis of gastric adenocarcinoma.
    Li P; Sun D; Li X; He Y; Li W; Zhao J; Wang Y; Wang H; Xin Y
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1765-73. PubMed ID: 27325246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
    Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
    Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NEDD9 overexpression correlates with poor prognosis in gastric cancer.
    Liu Y; Wang D; Zhao KL; Zhu JW; Yin HB; Wei YZ; Wu ZJ; Cheng GJ; Wang F; Ni F; Wang XL; Cao GX; Huang J; Cai J
    Tumour Biol; 2014 Jul; 35(7):6351-6. PubMed ID: 24664584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.
    Jeong W; Kim SB; Sohn BH; Park YY; Park ES; Kim SC; Kim SS; Johnson RL; Birrer M; Bowtell DSL; Mills GB; Sood A; Lee JS
    Anticancer Res; 2014 Feb; 34(2):811-817. PubMed ID: 24511017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome.
    Rybarczyk A; Klacz J; Wronska A; Matuszewski M; Kmiec Z; Wierzbicki PM
    Oncol Rep; 2017 Jul; 38(1):427-439. PubMed ID: 28504812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.
    Ajani JA; Estrella JS; Chen Q; Correa AM; Ma L; Scott AW; Jin J; Liu B; Xie M; Sudo K; Shiozaki H; Badgwell B; Weston B; Lee JH; Bhutani MS; Onodera H; Suzuki K; Suzuki A; Ding S; Hofstetter WL; Johnson RL; Bresalier RS; Song S
    Br J Cancer; 2018 Jan; 118(1):52-61. PubMed ID: 29136404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer.
    Chen MJ; Wang YC; Wu DW; Chen CY; Lee H
    Pathol Res Pract; 2019 Apr; 215(4):801-806. PubMed ID: 30685130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.
    Lee K; Lee KB; Jung HY; Yi NJ; Lee KW; Suh KS; Jang JJ
    BMC Cancer; 2017 Jun; 17(1):441. PubMed ID: 28645247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
    Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
    Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.